US3896226A - 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist - Google Patents

6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist Download PDF

Info

Publication number
US3896226A
US3896226A US446498A US44649874A US3896226A US 3896226 A US3896226 A US 3896226A US 446498 A US446498 A US 446498A US 44649874 A US44649874 A US 44649874A US 3896226 A US3896226 A US 3896226A
Authority
US
United States
Prior art keywords
methylene
desoxy
set forth
compound
narcotic antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US446498A
Inventor
Jack Fishman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEWINSTEIN EVALINA
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
LEWINSTEIN EVALINA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US00202575A external-priority patent/US3814768A/en
Application filed by LEWINSTEIN EVALINA filed Critical LEWINSTEIN EVALINA
Priority to US446498A priority Critical patent/US3896226A/en
Application granted granted Critical
Publication of US3896226A publication Critical patent/US3896226A/en
Assigned to PHARMEDIX INTERNATIONAL LTD., 8800 N.W. 36TH STREET, MIAMI, FLORIDA A BERMUDA CORP. reassignment PHARMEDIX INTERNATIONAL LTD., 8800 N.W. 36TH STREET, MIAMI, FLORIDA A BERMUDA CORP. ASSIGNMENT OF 1/2 OF ASSIGNORS INTEREST Assignors: HIRSCH, HENRY, ROTHSCHILD, STANLEY, I.,
Assigned to PHARMEDIX INTERNATIONAL, LTD., A BERMUDA CORP. reassignment PHARMEDIX INTERNATIONAL, LTD., A BERMUDA CORP. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: HIRSCH, HENRY. EXECUTORS OF THE ESTATE OF EVALINA LEWENSTEIN, DEC'D, ROTHSCHILD, STANLEY, I., EXECUTORS OF THE ESTATE OF EVALINA LEWENSTEIN, DEC'D
Assigned to HIRSCH, HENRY AND ROTHSCHILD, STANLEY, EXECUTORS OF THE ESTATE OF EVALINA LOWENSTEIN, DEC'D reassignment HIRSCH, HENRY AND ROTHSCHILD, STANLEY, EXECUTORS OF THE ESTATE OF EVALINA LOWENSTEIN, DEC'D LETTERS OF TESTAMENTARY (SEE DOCUMENT FOR DETAILS). Assignors: LEWENSTEIN, EVALINA, DEC'D
Assigned to PHARMEDIX, INC. reassignment PHARMEDIX, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: PHARMEDIX INTERNATIONAL, LTD.
Assigned to BAKER CUMMINS PHARMACEUTICALS, INC. reassignment BAKER CUMMINS PHARMACEUTICALS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). FILED AUGUST 17, 1988. DELAWARE Assignors: IVAX PHARMACEUTICALS, INC.
Assigned to BAKER CUMMINS LABORATORIES, INC. reassignment BAKER CUMMINS LABORATORIES, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). FILED NOVEMBER 10, 1988. DELAWARE Assignors: BAKER CUMMINS PHARMACEUTICALS, INC.,
Assigned to IVAX PHARMACEUTICALS, INC. reassignment IVAX PHARMACEUTICALS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). FILED FEBRUARY 16, 1988 Assignors: PHARMEDIX, INC.
Assigned to BAKER CUMMINS PHARMACEUTICALS, INC. reassignment BAKER CUMMINS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BAKER CUMMINS LABORATORIES, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Definitions

  • novel compounds can be combined to form metal salts thereof as, for example, combined with alkali metal and alkaline earth metal salts, sodium salts being the preferred form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A narcotic antagonist selected from the group consisting of 6methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof which are particularly effective by the oral route and which are also effective when administered parenterally.

Description

United States Patent [1 1 Fishman 1 6-METHYLENE-6-DESOXY DIHYDRO MORPHINE AND CODEINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND USE OF THE SAME AS A NARCOTIC ANTAGONIST [75] Inventor: Jack Fishman, New York, N.Y.
[73] Assignees: Evalina Lewinstein; Henry Hirsch;
Stanley Rothschild, all of New York, N.Y.
[22] Filed: Feb. 27, 1974 21 Appl. No.: 446,498
Related U.S. Application Data [63] Continuation-impart of Ser. No. 202,575, Nov. 26,
1971, Pat. No. 3,814,768.
[ 51 July 22,1975
3,322,771 5/1967 Bartels-Keith 260/285 3,332,950 7/1967 Blumberg 3,773,955 11/1973 Pacter et al 424/260 FOREIGN PATENTS OR APPLICATIONS 101,153 10/1963 Japan 260/285 OTHER PUBLICATIONS Gates et al., J. Med. Chem., Vol. 7, pp. 127-131, (1964).
Martin et al., Long Acting Narcotic Antagonists, N.I.M.I-l., pp. 21-29.
Primary Examiner-Albert T. Meyers Assistant Examiner-Norman A. Drezin Attorney, Agent, or Firm-Kirschstein, Kirschstein, Ottinger, & Frank [57] ABSTRACT A narcotic antagonist selected from the group consisting of 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof which are particularly effective by the oral route and which are also effective when administered parenterally.
19 Claims, No Drawings 1 6-METHYLENE-6-DESOXY DIHYDRO MORPHINE AND CODEINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND USE OF THE SAME AS A NARCOTIC ANTAGONIST CROSS REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of application Ser. No. 202,575 filed Nov. 26, 1971 now US. Pat. No. 3,814,768 for 6-METHYLENE-6-DESOXY Dl- HYDRO MORPHINE AND CODEINE DERIVA- TIVES AND PHARMACEUTICALLY ACCEPT- ABLE SALTS THEREOF.
BACKGROUND OF THE INVENTION l. Field of the Invention Narcotic antagonists.
2. Description of the Prior Art Narcotic antagonists are now entering into approved use for treatment of narcotic addiction. One such narcotic antagonist whose use has become popular is cyclazocine. A more effective narcotic antagonist is N- allyl-noroxymorphone known as naloxone. Naloxone has been a very effective narcotic antagonist when administered by a parenteral route at a dosage level of approximately 0.01 milligrams per kilogram of patient body weight. When so administered its narcotic antagonistic effect persists for approximately six hours. Naloxone is not as effective as a narcotic antagonist when administered orally. By the latter route larger doses are required, for example 25.0 milligrams per kilogram of patient body weight, and the duration of the effect is less than when administered parenterally, for example, about four hours. It is undesirable to administer a narcotic antagonist parenterally for psychological reasons. On the other hand, current narcotic antagonists are not satisfactory when given in oral doses because of the large amounts required, the necessity for concealing the taste of such large amounts and the short period of time between dosages. It would be highly desirable to supply a narcotic antagonist which could be administered orally in comparatively small dosages and which would have an appreciably longer lasting effect than either cyclazocine or naloxone.
SUMMARY OF THE INVENTION 1. Purposes of the Invention It is an object of the invention to provide a narcotic antagonist which is more effective than cyclazocine and naloxone when administered orally and which will have a longer lasting effect when so administered.
It is another object of the invention to provide a narcotic antagonist of the character described which is also capable of administration parenterally.
It is another object of the invention to provide a narcotic antagonist of the character described which is no more expensive or difficult to make than cyclazocine or naloxone and which is, therefore, less expensive to administer because of the lower dosages needed and the longer periods of effectiveness.
It is another object of the invention to provide a narcotic antagonist of the character described which may be made simply and quickly and on a large scale production basis so as to be able to administer the same to the many addicts'whichpresent-day' society unfortunately has produced.
R is selected from the group consisting of hydrogen and hydroxy (OH), and R is selected from the group consisting of hydroxy (OH) and methoxy (OCH and the pharmaceutically acceptable salts thereof. The said compound is combined (mixed) with a pharmaceutically acceptable inert carrier for easy ingestion. Any typical carrier well known in the art can be used, examples thereof being water, milk with or without sugar and/or starch, natural and synthetic fruit juice and beverages. If the compound is to be administered parenterally, distilled water is a desirable carrier. The narcotic antagonistic also may be administered rectally by incorporation in a standard suppository.
The invention consists in the compositions of matter and series of steps which will hereinafter be described and of which the scope of application will be indicated in the appended claims.
PREFERRED EMBODIMENTS OF THE INVENTION As indicated above, the present invention principally resides in a new compound of matter constituting a 6- methylene-6-desoxy dihydro morphine or codeine derivative of the formula where R, is selected from the group consisting of ally] and cyclopropylmethyl, R is selected from the group consisting of hydrogen and hydroxy, and R is selected from the group consisting of hydroxy and methoxy, and the pharmaceutically acceptable salts thereof. The aforesaid novel compounds, due to their high potency in small dosages, are preferably combined with a pharmaceutically acceptable inert carrier. Suitable inert carriers for oral administration are water, milk optionally with sugar and/or starch, natural and synthetic fruit juices, such as orange juice, grapefruit juice, grape juice, pineapple juice, lemon juice and prune juice, and sweetened beverages such, for instance, as flavored water with or without carbonation.
The following are specific examples of compounds of the present invention:
a. 6-methylene-6-desoxy-N-allyll 4-hydroxydihydronormorphine. b. 6-methylene-6-desoxy-N-cyclopropylmethyll 4- hydroxydihydronormorphine. c. 6-methylene-6-desoxy-N-cyclopropylmethyl dihydronormorphine.
6-methylene-6-desoxy-N-allyl-dihydronormorphine. e. 6-methylene-6-desoxyl 4-hydroxydihydronormorphine f. 6-methylene-6-desoxy-dihydronormorphine. g. 6-methylene-6-desoxy-N-allyl-dihydronorcodeine. h. 6-methylene-6-desoxy-N-cyclopropylmethy]-l4- hydroxydihydronorcodeine. i. 6-methylene-6-desoxy-N-allyl- 1 4- hydroxydihydronorcodeine. 6-methylene-6-desoxyl 4-hydroxydihydronorcodeine.
PREPARATION EXAMPLE l 30 grams of l4-hydroxydihydronormorphinone was converted to its sodium salt and suspended in 200 cc. of chloroform. 8 grams of chloromethyl ether in 50 cc. of chloroform were added and the mixture was stirred in a nitrogen atmosphere for ten hours. The solution was then washed with dilute NaOH and water, dried and evaporated. The 14- hydroxydihydronormorphinone-3-methoxymethyl ether thus obtained was crystallized from benzene.
grams of l4-hydroxydihydronormorphinone-3- methoxymethyl ether dissolved in the minimum amount of tetrahydrofuran was added slowly to a stirred solution of four equivalents of triphenylphosphomethylene reagent in ethyl ether. The ether was fractionally distilled off with periodic additions of tetrahydrofuran until the reflux temperature reached 60C. The solution was refluxed at this temperature for 40 hours, after which the solvent was removed under reduced pressure. The residue was taken up in 200 c.c.
of chloroform and 100 c.c. vof water. The water layer was discarded and the chloroform was washed once with 100 c.c. of 5%NaOH andthen extracted three times with 100 c.c. of 2N sulfuric acid. The acid extract 5 was quickly neutralized and adjusted to pH 9 with concentrated ammonium hydroxide and the basic solution was extracted with four 100 c.c. portions of chloroform. The ketonic materials were removed from the organic layer by washing with sodium bisulfite-sodium sulfite solution, and the chloroform was dried over sodium sulfate and evaporated. The residue was crystallized from ethanol-ether to give 3.9 grams of 6- methylene-6-desoxyl 4-hydroxydihydronormorphine- 3-methoxymethy] ether. l5 1 gram of 6-methylene-6-desoxy-l4- hydroxydihydronormorphine-3-methoxymethyl ether was dissolved in c.c. of 1N HC] and allowed to stand for four hours at room temperature. The addition of 100 c.c. of water was followed by adjusting the pH to 9 with ammonium hydroxide. The basic mixture was extracted three times with 100 c.c. of chloroform which was dried and evaporated. Crystallization from dilute methanol gave 6-methylene-6-desoxy-l4- hydroxydihydronormorphine with a melting point of 246-250C.
50 grams of 6-methyIene-6-desoxy-l4-hydroxydihydronormorphine was dissolved in 200 c.c. of ethanol, half its weight of sodium bicarbonate and half its weight of allyl bromide was added and the mixture was refluxed at about 75C for 50 hours. The solution was cooled to room temperature, filtered and the alcohol was removed under reduced pressure. The residue was taken up in 100 c.c. of chloroform and filtered; the solvent was removed under reduced pressure and the residue was crystallized from benzene-hexane to give 6- methylene-6-desoxy-N-allyl-14-hydroxydihydronormorphine.
EXAMPLE I] 50 grams of 6-methylene-6-desoxy-l4-hydroxydihydronormorphine was reacted as above except that cyclopropylmethyl chloride was used instead of allyl bromide to give 6methylene-6-desoxy-N- cyclopropylmethyll 4-hydroxydihydronormorphine.
EXAMPLE ll] 2 grams of 6-methylene-6-desoxy-N-allyl-l4- hydroxydihydronormorphine was dissolved in 75 c.c. of ethanol and allowed to stand with excess diazomethane in ether for 48 hours at 5C. The solvents and excess reagent were then evaporated and the residue was crystallized from ethanol to give 6-methylene-6-desoxy-N- allyl-l4-hydroxydihydronorcodeine with a melting point of l72-l78C.
EXAMPLE IV 10 grams of N-allyl-dihydronormorphinone-3- methoxymethyl ether was dissolved in 100 c.c. of tetrahydrofuran and three. equivalents of triphenylphosphomethylene reagent in 100 c.c. of-tetrahydrofuran was added and the mixture was refluxed for three days. The reaction mixture was then cooled and the solvent was removedunder reduced pressure The residue was taken up in 300 c.c. of chloroform and filtered and the organic layer. was extracted three times with 100 c.c. of 10% aqueousHCl. The acidextract was quickly adjusted to pH 9 with concentrated ammonium hydroxide and extracted four times with 100 c.c. of chloroform, which was washed with water, dried and evaporated under reduced pressure. The residue was crystallized from ethanol to give 6-methylene-6-desoxy-N allyldihydronormorphine-3-methoxymethyl ether with a melting point of l9720lC.
5 grams of 6-methylene-6-desoxy-N-allyldihydronormorphine-3-methoxymethyl ether was allowed to stand in 5% sulfuric acid (aq.) for 4 hours at room temperature, and the solution was then adjusted to pH 9 with dilute NaOH. The precipitate so obtained was filtered, dried in air and recrystallized from methano] to give 6-methylene-6-desoxy-N-allyl-dihydronormorphine with a melting point of 235-24lC It has been found that a wide variety of salts of'the compounds embodying the present invention can be prepared. They include hydrochloride, hydrobromide, neutral and acid sulfate, phosphates, nitrate, acetate, benzoate, salicylate, neutral and acid fumarate and maleate, terephthalate, ethanesulfonate, the bitartrate and others.
Water-soluble salts with volatile acids (e.g. hydrochloric and acetic acid) can be prepared by adding an aqueous solution of slightly more than one equivalent of the acid to an aqueous dispersion of the base and evaporating the solution thus formed under reduced pressure. The residue can then be recrystallized. Salts of non-volatile inorganic acids (e.g. orthophosphoric acid) can be prepared by adding the stoichiometric amount of the acid to an aqueous dispersion of the base and treating the resulting solution in the manner described above. Salts of organic acids which are difficultly soluble in water (e.g., the benzoate) can be prepared by reacting the acid and the base in equivalent amounts in ethyl alcoholic medium and evaporating the solution.
EXAMPLE V 100 mg. of 6-methylene-6-desoxy-N-allyl-l4- hydroxydihydronormorphine was dissolved in 20 c.c. of dilute ethanol. Excess dilute hydrochloric acid (10 c.c.) was added, and the mixture was evaporated to dryness under reduced pressure on a steam bath. The white hydrochloride salt was crystallized from ethanolether.
EXAMPLE VI 100 mg. of 6-methylene-6-desoxy-N-allyl-14- hydroxydihydronormorphine was dissolved in ml. of ethanol. A solution of 39 mg. of benzoic acid in 5 c.c. of ethanol was added and the solvent was evaporated under reduced pressure on a steam bath. The white benzoate was crystallized from ethanol-ether.
Furthermore, the novel compounds can be combined to form metal salts thereof as, for example, combined with alkali metal and alkaline earth metal salts, sodium salts being the preferred form.
As indicated previously, a highly effective oral dosage of 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof constitutes 0.1 milligrams to 10.0 milligrams per kilogram of patient body weight at which rate the duration of the narcotic antagonist effect persists for approximately eight to twelve hours. The dilution of the aforesaid novel compound in any one of the carriers mentioned above can vary as desired, a typical dilution being 0.5% to 5.0% by weight of the compound in any of the aforesaid inert carriers. Although as mentioned above the novel compounds are believed to find their most effective use when employed orally, they also can be administered parenterally and, in this event,
a dilution which obtains satisfactory results is 0.5 to 2% by weight of the compound in distilled water. Excellent narcotic antagonist effects are observed with dosages in the order of 0.02 to 2.0 milligram of the compound per kilogram of patient body weight. The compounds also can be administered rectally by incorporating the same in a suppository, e.g. of the petrolatum or wax type.
It thus will be seen that'there have been provided compositions and methods for narcotic antagonists which accomplish the various objects of the invention and are well adapted to meet the conditions of practical use.
As various possible embodiments might be made of the above invention and as changesmight be made in the embodiments above set forth, it is to be understood that all matter herein described is to be interpreted as illustrative and not in a limiting sense.
Having thus described the invention there is claimed as new and desired to be secured by Letters Patent:
1. A narcotic antagonist composition comprising a. an effective amount of a compound selected from the group consisting of those having the formula and pharmaceutically acceptable salts thereof where R, is selected from the group consisting of allyl and cyclopropylmethyl, R is selected from the group consisting of hydrogen and hydroxy, and R is selected from the group consisting of hydroxy and methoxy, and
b. a pharmaceutically acceptable inert carrier.
2. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxy-N-allyll 4-hydroxydihydronormorphine.
3. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxy-N-cyclopropylmethyl- 1 4-hydroxydihy dronormorphine.
4. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxy-N-cyclopropylmethyl-dihydronormorphine.
5. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxy-N-allyl-dihydronormorphine.
6. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxy- 1 4-hydroxydihydronormorphine.
7. a narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxydihydronormorphine.
8. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxy-N-allyl-dihydronorcodeine.
9. A narcotic antagonist compositionasset forth in claim 1 wherein the' compound is 6-methy lene6- desoxy-N-cyclopropylmethylr14- hydroxydihydronorcodeine.
10. A narcotic antagonist composition asset forth in claim 1 wherein the compound is 6-methylene-6- desoxy-N-allyl-l 4-hydroxydihydronorcodeine.
11. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6- desoxyl 4-hydroxydihydronorcodeine.
12. A narcotic antagonist composition as set forth in claim 1 wherein the compound is from 0.5% to 2% by weight of the composition.
13. A narcotic antagonist composition as set forth in claim 12 wherein the inert carrier is water.
14. A method of antagonizing narcotics in a patient in need thereof which comprises administering to said patient an effective amount of the composition of claim 1, providing from 0.02 to 10.0 milligrams per kilogram of patient body weight of said compound.
15 A method as set forth in claim 14 wherein the composition is administered orally.
16. A method as set forth in claim 15 wherein the dosage is from 0.1 to 10.0 milligrams of the compound per kilogram of patient body weight.
17. A method as set forth in claim 14 wherein the composition is administered parenterally.
18. a method as set forth in claim 17 wherein the dosage is from 0.02 to 2.0 milligrams of the compound per kilogram of patient body weight.
19. A method as set forth in claim 14 wherein the composition is administered rectally.

Claims (19)

1. A NARCOTIC ANTAGONIST COMPOSITION COMPRISING A. AN EFFECTIVE AMOUNT OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF THOSE HAVING THE FORMULA
2. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-N-allyl-14-hydroxydihydronormorphine.
3. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphine.
4. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-N-cyclopropylmethyl-dihydronormorphine.
5. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-N-allyl-dihydronormorphine.
6. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-14-hydroxydihydronormorphine.
7. a narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxydihydronormorphine.
8. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-N-allyl-dihydronorcodeine.
9. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronorcodeine.
10. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-N-allyl-14-hydroxydihydronorcodeine.
11. A narcotic antagonist composition as set forth in claim 1 wherein the compound is 6-methylene-6-desoxy-14-hydroxydihydronorcodeine.
12. A narcotic antagonist composition as set forth in claim 1 wherein the compound is from 0.5% to 2% by weight of the composition.
13. A narcotic antagonist composition as set forth in claim 12 wherein the inert carrier is water.
14. A method of antagonizing narcotics in a patient in need thereof which comprises administering to said patient an effective amount of the composition of claim 1, providing from 0.02 to 10.0 milligrams per kilogram of patient body weight of said compound.
15. A method as set forth in claim 14 wherein the composition is administered orally.
16. A method as set forth in claim 15 wherein the dosage is from 0.1 to 10.0 milligrams of the compound per kilogram of patient body weight.
17. A method as set forth in claim 14 wherein the composition is administered parenterally.
18. a method as set forth in claim 17 wherein the dosage is from 0.02 to 2.0 milligrams of the compound per kilogram of patient body weight.
19. A mEthod as set forth in claim 14 wherein the composition is administered rectally.
US446498A 1971-11-26 1974-02-27 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist Expired - Lifetime US3896226A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US446498A US3896226A (en) 1971-11-26 1974-02-27 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US00202575A US3814768A (en) 1971-11-26 1971-11-26 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US446498A US3896226A (en) 1971-11-26 1974-02-27 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist

Publications (1)

Publication Number Publication Date
US3896226A true US3896226A (en) 1975-07-22

Family

ID=26897815

Family Applications (1)

Application Number Title Priority Date Filing Date
US446498A Expired - Lifetime US3896226A (en) 1971-11-26 1974-02-27 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist

Country Status (1)

Country Link
US (1) US3896226A (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4477457A (en) * 1982-10-28 1984-10-16 E. I. Du Pont De Nemours And Company Method for inducing anorexia using nalmetrene
US4478840A (en) * 1983-10-11 1984-10-23 E. I. Du Pont De Nemours And Company Appetite suppressing compositions and methods
US4751307A (en) * 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4785000A (en) * 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1989010125A1 (en) * 1988-04-27 1989-11-02 Baker Cummins Pharmaceuticals, Inc Method of reversing the side effects of epidural analgesics
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
US4972308A (en) * 1990-01-16 1990-11-20 Chen I Ming Innovated lamp fitting set without welding
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5668285A (en) * 1986-10-31 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates
US5783583A (en) * 1996-04-12 1998-07-21 Simon; David Lew 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US5922705A (en) * 1996-04-12 1999-07-13 Intensive Narcotic Detoxification Centers Of America, Llc Rapid narcotic detoxification
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US20030026838A1 (en) * 2001-06-26 2003-02-06 Farrell John J. Tamper-proof narcotic delivery system
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20090076052A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched nalmefene
WO2013083685A1 (en) * 2011-12-06 2013-06-13 H. Lundbeck A/S Process for recovery of nalmefene hydrochloride

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153042A (en) * 1964-10-13 Morphinone and codeinone derivatives
US3162639A (en) * 1964-12-22 G-desoxy-ix-hydroxy-dihydromorphine
US3322771A (en) * 1967-05-30 Intermediates for preparing thebaine derivatives
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153042A (en) * 1964-10-13 Morphinone and codeinone derivatives
US3162639A (en) * 1964-12-22 G-desoxy-ix-hydroxy-dihydromorphine
US3322771A (en) * 1967-05-30 Intermediates for preparing thebaine derivatives
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4477457A (en) * 1982-10-28 1984-10-16 E. I. Du Pont De Nemours And Company Method for inducing anorexia using nalmetrene
US4478840A (en) * 1983-10-11 1984-10-23 E. I. Du Pont De Nemours And Company Appetite suppressing compositions and methods
US4751307A (en) * 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
US4785000A (en) * 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5668285A (en) * 1986-10-31 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates
WO1989010125A1 (en) * 1988-04-27 1989-11-02 Baker Cummins Pharmaceuticals, Inc Method of reversing the side effects of epidural analgesics
US4972308A (en) * 1990-01-16 1990-11-20 Chen I Ming Innovated lamp fitting set without welding
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US5922705A (en) * 1996-04-12 1999-07-13 Intensive Narcotic Detoxification Centers Of America, Llc Rapid narcotic detoxification
US6087356A (en) * 1996-04-12 2000-07-11 Simon; David Lew Rapid narcotic detoxification
US5783583A (en) * 1996-04-12 1998-07-21 Simon; David Lew 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US20030026838A1 (en) * 2001-06-26 2003-02-06 Farrell John J. Tamper-proof narcotic delivery system
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20090076052A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched nalmefene
WO2013083685A1 (en) * 2011-12-06 2013-06-13 H. Lundbeck A/S Process for recovery of nalmefene hydrochloride
US8841452B1 (en) 2011-12-06 2014-09-23 H. Lundbeck A/S Process for recovery of nalmefene hydrochloride
CN104093721A (en) * 2011-12-06 2014-10-08 H.隆德贝克有限公司 Process for recovery of nalmefene hydrochloride
CN104093721B (en) * 2011-12-06 2016-05-18 H.隆德贝克有限公司 For reclaiming the method for nalmefene hydrochloride
RU2631652C2 (en) * 2011-12-06 2017-09-26 Х. Лундбекк А/С Method for extracting nalmephene hydrochloride

Similar Documents

Publication Publication Date Title
US3896226A (en) 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
US3814768A (en) 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4272541A (en) 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4218470A (en) Epinine esters and pharmaceutical compositions thereof
US3320262A (en) 14 hydroxy morphine and codeine carboxymethyloximes
GB1234508A (en)
JPH085864B2 (en) Novel aconitine compounds and analgesic / anti-inflammatory agents containing them as active ingredients
US3135758A (en) Morphinone and codeinone derivatives
US4183939A (en) Glaucine analgesic method
JP3117251B2 (en) 14-Op-chlorobenzoyl aconine and analgesic / anti-inflammatory agent
US4265912A (en) Glaucine lactate salts
US3317544A (en) 3-tropinyl esters of substituted acrylic and thio acrylic acids
US3005818A (en) 1-phenyl-2, 3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds
JPH085865B2 (en) Novel aconitine compounds and analgesic / anti-inflammatory agents containing them as active ingredients
US2984674A (en) Amides of podophyllic acid and picropodophyllic acid
US3449332A (en) Novel methanobenzazocines and processes
US4334071A (en) 17-Cyclobutylmethyl-3-hydroxy-8β-methyl-6-methylene-morphinane methanesulfonate
Robison et al. Rauwolfia alkaloids XXXV. potent, fast-acting sedatives derived from methyl reserpate
US4048178A (en) Novel N-allyl and N-propargyl benzmorphan derivatives
US3328245A (en) Methods of use of tetrahydroisoquinoline antitussive
US3763184A (en) Pharmaceutically active pyrrolidino naphthothiophenes
US3359161A (en) Thiaxanthenols, process of producing and anti-tussive compositions thereof
US2933500A (en) Nu-aminoindolobenzoquinolizinium compounds
US2946797A (en) N-aminotetrahydroisoquinolinium salts
CA1109473A (en) Glaucine lactate salts

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED FILE - (OLD CASE ADDED FOR FILE TRACKING PURPOSES)

AS Assignment

Owner name: PHARMEDIX INTERNATIONAL LTD., 8800 N.W. 36TH STREE

Free format text: ASSIGNMENT OF 1/2 OF ASSIGNORS INTEREST;ASSIGNORS:ROTHSCHILD, STANLEY, I.,;HIRSCH, HENRY;REEL/FRAME:004940/0096

Effective date: 19871120

AS Assignment

Owner name: PHARMEDIX INTERNATIONAL, LTD., A BERMUDA CORP.,FL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROTHSCHILD, STANLEY, I., EXECUTORS OF THE ESTATE OF EVALINA LEWENSTEIN, DEC'D;HIRSCH, HENRY. EXECUTORS OF THE ESTATE OF EVALINA LEWENSTEIN, DEC'D;REEL/FRAME:004840/0088

Effective date: 19871214

Owner name: HIRSCH, HENRY AND ROTHSCHILD, STANLEY, EXECUTORS O

Free format text: LETTERS OF TESTAMENTARY;ASSIGNOR:LEWENSTEIN, EVALINA, DEC'D;REEL/FRAME:004840/0091

Effective date: 19871222

Owner name: PHARMEDIX INTERNATIONAL, LTD., 8800 N.W. 36TH STEE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST. ASSIGNS THE ENTIRE UNDIVIDED ONE-HALF INTEREST.;ASSIGNORS:ROTHSCHILD, STANLEY, I., EXECUTORS OF THE ESTATE OF EVALINA LEWENSTEIN, DEC'D;HIRSCH, HENRY. EXECUTORS OF THE ESTATE OF EVALINA LEWENSTEIN, DEC'D;REEL/FRAME:004840/0088

Effective date: 19871214

AS Assignment

Owner name: PHARMEDIX, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:PHARMEDIX INTERNATIONAL, LTD.;REEL/FRAME:005043/0622

Effective date: 19871215

AS Assignment

Owner name: BAKER CUMMINS LABORATORIES, INC.

Free format text: CHANGE OF NAME;ASSIGNOR:BAKER CUMMINS PHARMACEUTICALS, INC.,;REEL/FRAME:005080/0956

Effective date: 19881027

Owner name: IVAX PHARMACEUTICALS, INC.

Free format text: CHANGE OF NAME;ASSIGNOR:PHARMEDIX, INC.;REEL/FRAME:005080/0950

Effective date: 19880203

Owner name: BAKER CUMMINS PHARMACEUTICALS, INC.

Free format text: CHANGE OF NAME;ASSIGNOR:IVAX PHARMACEUTICALS, INC.;REEL/FRAME:005080/0953

Effective date: 19880812

AS Assignment

Owner name: BAKER CUMMINS PHARMACEUTICALS, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BAKER CUMMINS LABORATORIES, INC.;REEL/FRAME:005120/0471

Effective date: 19890615